241 results about "Neoplasm diagnosis" patented technology

A method is provided for assessing allelic losses on specific chromosomal regions in melanoma patents. The method relies on the evidence that free DNA may be released in the plasma/serum of cancer patients allowing the detection of DNA with LOH in the plasma/serum of cancer patients by analysis for microsatellite markers. The amount of and specific allelic loss allows a prognosis to be made regarding tumor diagnosis and progression, tumor metastasis, tumor recurrence, and mortality.

The invention relates to a mouse monoclonal antibody of anti-human carcino-embryonic antigen (CEA) resisting colorectal neoplasm activity, prepared by a biological technology. The method comprise a method for detecting CEA family protein by utilizing the antigen-combining capacity specificity of the mouse monoclonal antibody CC4 of anti-human CEA and a neoplasm treatment method by utilizing the colorectal neoplasm activity. The antibody can be used for specifically recognizing the human CEA at molecular, cellular and texture levels and recognizing a special antigen epiposition widely distributed in the CEA family protein. The CC4 is specifically combined with colorectal neoplasm texture at the texture level and presents stronger capabilities of restraining neoplasm growth, neoplasm metastasis, neoplasm invasion in an animal model and at the cellular level. The antibody and detection and treatment methods based on the antibody can become an effective neoplasm diagnosis and treatment tool in basal research or clinical application.

A field effect transistor-based rapid human tumor diagnosis apparatus comprises a field effect transistor biochip, a microfluidic channel sample packaging system and a set of electronic detection system. The semiconductor manufacturing technology is utilized to construct a source electrode, a drain electrode and a semiconductor channel between the source electrode and the drain electrode on a silicon substrate, silane reagent is covalently modified on the channel to serve as connecting molecules, which are connected with the specific antibody protein of a certain tumor marker, a microfluidic channel which is constructed with polydimethylsiloxane is then tightly attached and packaged on the silicon substrate, and finally, the source electrode and the drain electrode are connected with the signal detection system. By assaying the tumor marker in human blood, the tumor diagnosis apparatus can rapidly, accurately and early diagnose whether a patient suffers from a certain type of cancer, and is an integrated, high-flux and portable tumor diagnosis apparatus.

Provided herein is a breast ultrasound scanning and diagnosis aid system. The scanning aid system is capable of aiding positioning and tracking the scanned breast ultrasound images and suspicious tumor ultrasound images so that the doctor can be easily informed of the scanned positions of the breast ultrasound images and the suspicious tumor ultrasound images. The diagnosis aid system selects at least one representative, breast ultrasound images with tumor characteristics, segments a suspicious tumor region, and acquires a plurality of characteristic parameters in association with tumor tissues from the suspicious tumor region so as to provide a diagnostic suggestion. With the use of the present invention, the positions of suspicious tumors can be acquired from the positioning data of the breast ultrasound images, and tumor diagnosis accuracy can be improved by selecting an ultrasound image with tumor characteristics.

The invention relates to the field of genetic engineering and biotechnologic detection, and concretely relates to a gene group and a kit for diagnosing lung cancer, and a diagnosis method thereof. The gene group for diagnosing the lung cancer includes ABCB1, AKT1, ALK, APC, ATIC and other 63 genes. The method using the gene group to diagnose the lung cancer comprises the following steps: (1) extracting free DNA and genome DNA from the plasma of a sample to be detected; and (2) breaking the genome DNA into fragments with the length of 150-250 bp, carrying out hybrid capture on the broken genome DNA and the free DNA to construct a DNA library, carrying out online sequencing, and analyzing the obtained sequencing result. Exon and partial intron regions of the 68 genes of the free DNA are enriched at one time by a probe capture technology to realize multi-gene and multi-target parallel deep high-throughput sequencing with high accuracy, optimize the detection flow and improve the detection precision, so liquid biopsy, low-frequency detection and tumor diagnosis become possible.

The invention provides a high-specificity high-sensitivity coordinated compound anti-human-TK1 antibody prepared from an antigenic determinant composed of human cervical cancer cell TK1 monomer N-terminal 23 peptide, C-terminal 20 peptide and C-terminal 28 peptide, and application thereof in tumor diagnosis. The antigenic determinant contains the following amino acid sequences: N-terminal 23 peptide (3-25): CINLPTVLPGSPSKTRGQIQVIL, C-terminal 20 peptide (206-225) CPVPGKPGEAVAARKLFAPQ, and C-terminal 28 peptide (198-225) AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention also relates to a method for preparing the antibody prepared from the antigen. The antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like. The treatment effect on the tumor patient is evaluated by an enhanced chemiluminescent point blotting detection method, immunohistochemical detection and the detection kit.

The invention discloses a methylation marker for early diagnosis of tumors. The marker comprises CpG islands corresponding to 248 probes in a HumanMethylation450BeadChip Kit and can well separate tumor tissue of the tumors in a training set from pericarcinomatous normal tissue. According to the methylation marker, a machine learning model constructed by adopting the methylation level of the markercan not only be used for clinically predicting the risk of 12 tumors in the training set, but also be applied to other tumors, and has good performance in the other tumors, and the area under the curve reaches 0.94; and it is proved that the methylation level of the screened CpG islands can be used for early diagnosis of almost all TCGA tumors. The invention further provides application of the CpG islands corresponding to 515 methylation markers in the HumanMethylation450BeadChip Kit in classification of the tumors and identification of tumor types.

The invention discloses a clinical decision supporting system of tumor diagnosis and treatment. The clinical decision supporting system comprises a data layer, an application layer and a user layer, wherein the application layer comprises a cache; the user layer comprises an input module and a client side, wherein the client side comprises a comparison module; the comparison module is connected with a tumor specialized knowledge base and a clinic path module; the comparison module outputs tumor staging information after the comparison module is compared with the tumor specialized knowledge base according to diagnosis information input by the input module; the clinic path module calls a diagnosis and treatment measure according to the output tumor staging information; and the comparison module compares the diagnosis information of a patient with the tumor diagnosis information in the tumor specialized knowledge base, and carries out continuous output on a comparison result by the output of a diagnosis byte to form tumor staging information. The clinical decision supporting system greatly improves the diagnosis efficiency of a tumor doctor and the stability of a diagnosis result, liberates more time and vigor of a tumor specialist to focus on the fine differentiation of a tumor case, and provides directional reference and guidance for forming a final tumor treatment scheme.

The invention provides a nanometer probe. First, a ferroferric oxide magnetic nanometer particle is synthesized by using a coprecipitation method or a high temperature decomposition method; and then the surface of the ferroferric oxide magnetic nanometer particle is modified so that the surface of the magnetic nanometer particle carries functional groups like a hydroxyl, an amino, a carboxyl, a sulfydryl or the like; and a photodynamic drug is coupled with the functional groups on the surface of the magnetic nanometer particle by using a covalent chemical reaction. The nanometer probe prepared by the invention is of spherical shape, has uniform granularity and has an average particle size of less than 50 nm, can be stably dispersed in an aqueous solution; and the preparation can generate a photodynamic effect while irradiated by light with proper wavelengths. The magnetic nanometer particle can be used for magnetically targeted drug transportation, nuclear magnetic resonance imaging and thermal therapy; photosensitizer drugs can be used for near infrared imaging and photodynamic therapy; and the invention is a novel nanometer probe integrated with magnetic target, thermal therapy and photodynamic therapy and provided with an imaging effect.

The invention provides a high-specificity and high-sensitivity coordination combination anti-human TK1 antibody prepared from an antigenic determinant consisting of 23 peptide at an N end, 20 peptide at a C end and 28 peptide at the C end of human cervical cancer cells, and application thereof to tumor diagnosis. The antigenic determinant comprises the following amino acid sequences: 1) the 23 peptide (3-25) at the N end: CINLPTVLPGSPSKTRGQIQVIL: 2) the 20 peptide (206-225) at the C end: CPVPGKPGEAVAARKLFAPQ; and 3) the 28 peptide at the C end: AGPDNKENCPVPGKPGEAVAARKLFAPQ. The invention simultaneously provides a method applying the antigen for preparing the antibody. An antibody kit provided by the invention has the characteristics of high sensitivity, high specificity, low cost and the like, tumor rehabilitation populations are periodically monitored by an enhanced chemiluminescence dot blot detection method, immunohistochemistry detection and the detection kit, and the recurrence and transfer risk and the prognosis of the tumor rehabilitation people are evaluated.

The invention provides recombined II-type herpes simplex virus. In the virus, ICP34.5 gene of a wild II-type herpes simplex virus HG52 strain is excluded, and a fluorescent protein expression box is inserted in the gene group. The invention also provides a preparation method of the recombined II-type herpes simplex virus, the application of the recombined II-type herpes simplex virus in preparation of the drug for diagnosing tumours, and a tumour diagnostic reagent kit with the recombined II-type herpes simplex virus. In the recombined II-type herpes simplex virus disclosed by the invention, the ICP34.5 gene is excluded, so that the recombined II-type herpes simplex virus can selectively grow and breed in tumour cells, the recombined II-type herpes simplex virus is inserted in the fluorescent protein expression box and can give out fluorescence in tumour cells, so that the tumour diagnostic reagent kit with the recombined II-type herpes simplex virus can quickly, accurately, sensitively and broadly detect whether a sample to be detected contains tumour cells or not.

The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a copper (Cu)-based nanoparticle and a method for making the same. The Cu-based nanoparticles can further be incorporated with additional therapeutic or diagnostic compounds and used for the diagnosis and treatment of tumors.

The present invention relates to a method for investigating body fluids for cancer cells, the use thereof and corresponding analysis kits, and the possibilities for cancer treatment derived therefrom. The method is based essentially on determining the expression of the manganese superoxide dismutase, thioredoxin reductase and/or glutathione peroxidase genes. Use of this method permits in particular reliable tumor diagnosis and prognosis. Diminishing an elevated expression of these genes has therapeutic value and may be utilized for cancer treatment.

The invention relates to an SNCG (synuclein gamma) monoclonal antibody and application thereof. The monoclonal antibody is secreted by a hybridoma cell line of which the preservation number is CGMCC No. 2468, or CGMCC No. 2469. The monoclonal antibody has high sensitivity and specificity, can recognize endogenous SNCG protein and be used for various types of immunological detection, can be applied to the level detection of SNCG protein expression in clinical tissue specimens so as to predict the metastasis trend of tumors and the prognosis of patients, can be applied to the detection of SNCG protein in body fluid of suspected or tumor patients so as to help diagnose tumors, can improve the sensitivity and specificity of tumor diagnosis through the combination with reagents detecting other tumor markers, can help to dynamically observe tumor process and provide reference for individualized treatment protocols, and can also be used for related research and medicament development of SNCG.

In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.

The invention provides application of GPC1 protein as a tumor diagnosis marker. The GPC1 protein can be used for preparing a digestive system malignant tumor diagnosis reagent and kit as a tumor diagnosis marker. The tumor marker GPC1 provided by the invention can be proved to be suitably used as a diagnosis marker of tumor in a digestive system currently in a small-scale clinical sample, has better sensitivity and specificity compared with traditional AFP, CEA, CA199 and the like, and can be used as a tumor marker for mass survey.

A dual-antibody sandwith ELISA detecting method for human soluble p185HER-2 antigen features that the purified and coated P185HER-2 monoclonal antibody is bound to solid supporter, the specimen containing soluble p185HER-2, the purified standard p185HER-2 antigen and the coated antibody are incubated, and another purified and coated p185HER-2 monoclonal antibody marked by horseradish perioxidase is used as detecting antibody. It can be used for serum diagnosis of tumor.

The invention discloses application of miR-425 in tumor diagnosis, treatment and prognosis. Multiple biological characteristics of tumor including apoptosis, proliferation, drug susceptibility and the like disclosed by the invention are closely related to the expression quantity of miR-425. MiR-425 antagonist antimiR-425 can be used for significantly inhibiting proliferation of multiple types of tumor cells and the tumorigenic ability of the tumor cells in a nude mouse, and enhancing the tumor treatment capacity of chemotherapy drug cisplatin and the like in the nude mouse. The invention discloses a kit for tumor assisted diagnosis and patient survival prognosis, and the kit contains a primer sequence for the quantitative determination of miR-425; the invention also discloses a pharmaceutical composition for treating tumor, wherein the composition contains the miR-425 antagonist antimiR-425. The invention provides a novel method for assisted diagnosis and prognosis diagnosis of cancer. The invention discovers that the antimiR-425 has high clinical application value in the preparation of a tumor-treating medicine, and particularly provides a novel medicine and a treatment method for the effective treatment of lung cancer and liver cancer.

The invention provides a biodegradable poly-HPMA-Gd magnetic resonance imaging (MRI) probe used for inserting enzyme sensitive polypeptide GFLG into a poly-HPMA backbone structure. The molecular weight of a prepared polymer is basically controllable, the molecular weight is high, and the dispersion coefficient (PDI) is low; and linear HPMA-DOTA-Gd is obtained through coupling with Gd(III). The probe is an efficient nanoscale MRI probe with biocompatibility, and can be used for clinical tumor diagnosis and adjuvant therapy.

The invention discloses a manganese compound and a preparation method and application thereof, and relates to the technical field of magnetic resonance imaging (MRI). The manganese compound is dichloro-N-(2-propionic carbethoxy)-N,N-bis(2-picolyl) amine synthetic manganese, and the molecular formula is C17H21Cl2MnN3O2. The preparation method for the manganese compound comprises the following steps: dissolving ligand dichloro-N-(2-propionic carbethoxy)-N,N-bis(2-picolyl) amine and MnCl2 into aqueous solution in a molar ratio of 1 to 1, and controlling the temperature to be between 20 and 40 DEG C; and synthesizing ammonium chloride and a catalyst in a molar ratio of the ammonium chloride to the MnCl2 of 0.2 to 1, reacting the mixture at the temperature of 30 DEG C for 1 to 4 hours, purifying a product by using silica gel column chromatography, concentrating the product and removing the solution to obtain light yellow manganese compound. The manganese compound is applied in the aspect of magnetic resonance imaging in a liver cancer body; and compared with the blank aqueous solution without the manganese compound, the compound can remarkably improve the tumor diagnosis effect, has magnetic resonance imaging function and tumor targeting property, and can be used as a magnetic resonance imaging contrast agent for the tumor.

The invention provides a near-infrared fluorescent heptamethine cyanine dye and application thereof in preparation of a tumor diagnosis agent and/ or an imaging agent. The near-infrared fluorescent heptamethine cyanine dye is a compound DZ-1, wherein the side chain of the compound DZ-1 is (CH2)4SO3H, so that the compound DZ-1 can be directly dissolved in water; in addition, the near-infrared fluorescent heptamethine cyanine dye can be applied by intravenous injection during living imaging, thus achieving the same treatment and applying mode as clinic ICG (Indocyanine Green); the compound DZ-1 can be specifically absorbed by hepatoma carcinoma cell and is gathered at the tumor part to support no-intrusive NIRF imaging, so that the tumor growing part can be detected; the fluorescence intensity at the tumor part, the specificity and the targeting performance are prior to those of clinically-used ICG. Therefore, the tumor diagnosis agent and/ or the imaging agent adopting the compound DZ-1 are high in tumor targeting performance and high in stability.

The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.